Spillane A J, Thomas J M, Fisher C
Sarcoma Unit, Royal Marsden Hospital, London, England, UK.
Ann Surg Oncol. 2000 Apr;7(3):218-25. doi: 10.1007/BF02523657.
Epithelioid sarcoma is a rare high grade soft tissue sarcoma with a known propensity for locoregional recurrence. The literature is limited on other characteristics such as frequency of multifocal disease at presentation, the relationship of presenting size of the primary lesion to prognosis, and the ability of current staging systems to predict prognosis.
Review of the Royal Marsden National Health Service Trust (RMH) experience of 37 cases over 21 years.
The mean age was 29 years, with male predominance (2.7:1), and distal limb locations were most common (56%). Five patients presented with multifocal local disease. Median follow-up was 88 months in the 19 patients still alive. The 5- and 10-year actuarial overall survival was 70% and 42%, respectively. Tumors deep to the investing fascia had a worse prognosis than superficial tumors. Regional metastasis events were also associated with significantly worse overall survival. Local recurrence, size of 5 cm or larger, and regional metastasis events were predictive of worse distant metastasis-free survival. Tumor size (<5 cm vs. > or =5 cm), local recurrence events, sex, and site were not significant predictors of survival. The American Joint Committee on Cancer/International Union Against Cancer staging systems and the recently proposed RMH staging system of the Royal Marsden National Health Service Trust provided poor differentiation of prognosis in epithelioid sarcoma. The 5-year actuarial local recurrence rate was 35%. The 5-year actuarial regional nodal metastasis rate was 23%. The actuarial 5-year distant metastasis rate was 40%, with pleuropulmonary metastases the most common site of metastatic disease, and 35% of pleuropulmonary metastases presented with pleural effusion. Median post-distant metastasis survival was 8 months.
Epithelioid sarcoma has unusual clinical behavior compared with other high grade soft tissue sarcoma. It has a propensity for multifocal disease at presentation, local recurrence, regional metastasis, and particularly poor prognosis after regional or distant metastatic disease. Size and stage according to the American Joint Committee on Cancer/International Union Against Cancer are unreliable predictors of prognosis.
上皮样肉瘤是一种罕见的高级别软组织肉瘤,已知有局部区域复发倾向。关于其他特征的文献有限,如初诊时多灶性疾病的发生率、原发灶初诊大小与预后的关系以及当前分期系统预测预后的能力。
回顾皇家马斯登国民保健服务信托基金(RMH)21年间37例患者的经验。
平均年龄29岁,男性居多(2.7:1),最常见于肢体远端(56%)。5例患者初诊时为多灶性局部疾病。19例存活患者的中位随访时间为88个月。5年和10年精算总生存率分别为70%和42%。位于深筋膜以下的肿瘤预后比浅表肿瘤差。区域转移事件也与总生存率显著降低相关。局部复发、大小≥5 cm以及区域转移事件可预测远处无转移生存率较差。肿瘤大小(<5 cm与≥5 cm)、局部复发事件、性别和部位不是生存的显著预测因素。美国癌症联合委员会/国际抗癌联盟分期系统以及皇家马斯登国民保健服务信托基金最近提出的RMH分期系统在区分上皮样肉瘤预后方面效果不佳。5年精算局部复发率为35%。5年精算区域淋巴结转移率为23%。精算5年远处转移率为40%,胸膜肺转移是最常见的转移部位,35%的胸膜肺转移伴有胸腔积液。远处转移后的中位生存期为8个月。
与其他高级别软组织肉瘤相比,上皮样肉瘤具有不寻常的临床行为。它在初诊时易出现多灶性疾病、局部复发、区域转移,尤其是在区域或远处转移疾病后预后特别差。根据美国癌症联合委员会/国际抗癌联盟标准的大小和分期是不可靠的预后预测指标。